The DOI matches its Crossref record; 73 of the 74 references it cites were found in a registry or an index.
APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer’s Disease Phenotypes in Human iPSC-Derived Brain Cell Types
Open accessAbstract
The apolipoprotein E4 (APOE4) variant is the single greatest genetic risk factor for sporadic Alzheimer's disease (sAD). However, the cell-type-specific functions of APOE4 in relation to AD pathology remain understudied. Here, we utilize CRISPR/Cas9 and induced pluripotent stem cells (iPSCs) to examine APOE4 effects on human brain cell types. Transcriptional profiling identified hundreds of differentially expressed genes in each cell type, with the most affected involving synaptic function (neurons), lipid metabolism (astrocytes), and immune response (microglia-like cells). APOE4 neurons exhibited increased synapse number and elevated Aβ 42 secretion relative to isogenic APOE3 cells while APOE4 astrocytes displayed impaired Aβ uptake and cholesterol accumulation. Notably, APOE4 microglia-like cells exhibited altered morphologies, which correlated with reduced Aβ phagocytosis. Consistently, converting APOE4 to APOE3 in brain cell types from sAD iPSCs was sufficient to attenuate multiple AD-related pathologies. Our study establishes a reference for human cell-type-specific changes associated with the APOE4 variant. VIDEO ABSTRACT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“induced pluripotent stem cells (iPSC)-derived neurons from LOAD patients expressing ApoE4 secrete higher levels of Aβ, when compared to ApoE3-expressing neurons”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [39]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, APOE4 was found to reduce the phagocytosis ability of glial cells, enhance microglia proinflammatory activation by Aβ plaques or tau aggregates and promote neurodegeneration in the mouse models.176,177”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [177]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies that have successfully targeted APOE using gene editing in induced pluripotent stem cells (iPSCs) provide strong proof of concept that in vitro editing of ε4 to ε3 or ε2 simultaneously ‘corrects’ several phenotypes, including glial transcriptomic profiles, lipid metabolism and other functional measures7,8.”
From APOE4 to APOE2 allelic switching in mice improves Alzheimer’s disease-related metabolic signatures, neuropathology and cognition (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In disease models, ApoE4 perturbs cholesterol regulation, including expression of cholesterol metabolism-related genes, cholesterol transport and esterification10–13.”
From Decreased lipidated ApoE‐receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The characterization of hIPSC-derived neurons indicates that neuronal APOE4 is associated with altered synaptic function, fatty acid accumulation and hyperexcitability143.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [143]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Astrocytes derived from APOE4 human-inducible pluripotent stem cells (hiPSCs) are less efficient at secreting lipidated APOE particles and exhibit impaired cholesterol metabolism relative to APOE3 hiPSC-derived astrocytes143,144.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [143]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 astrocytes have an increased number of lipid droplets and impaired glucose utilization and mitochondrial function, lending further support to this hypothesis143,146,147 (Fig. 2b).”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [143]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies with human iPSC-derived neurons and organoids confirm that apoE4 increases Aβ production and aggregation as well as decreases Aβ clearance”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Lin et al 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies with human iPSC-derived neurons and cerebral organoids demonstrate that apoE4 enhances tau phosphorylation and exacerbates synapse loss and neurodegeneration”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Lin et al 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies on human induced pluripotent stem cells (iPSCs) with the APOE4 variant showed altered transcriptomic and metabolomic profiles toward the accumulation of cholesterol in glia, such as astrocytes and oligodendrocytes.5”
From ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three ApoE3 and ApoE4 isogenic iPSCs pairs were used to determine the effect of APOE4 genotype without inter-donor variability.5”
From ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple transcriptomic studies of APOE4-expressing iPSC-derived astrocytes and microglia demonstrate alterations in the expression of lipid metabolic genes as well as defects in cholesterol trafficking and metabolism (Lin et al., 2018; de Leeuw et al., 2022; Tcw et al., 2022).”
From APOE traffics to astrocyte lipid droplets and modulates triglyceride saturation and droplet size (2024) · cites this paper as Lin et al., 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CRISPR/Cas9 technology, which allow precise genetic modifications, was used to convert APOE ε4 into APOE ε3 in neuronal, astrocytic and microglial cells types from iPSCs derived from LOAD patients, which led to the attenuation of some AD-related pathologies, namely Aβ glial uptake [39].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The fact that human iPSC-derived APOE4/E4 astrocytes were recently reported to accumulate endolysosomal cholesterol”
From TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge (2020) · cites this paper as Lin et al., 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE4 drives the accumulation of lipids and increased inflammatory cytokine production in vitro in human induced pluripotent stem cell (iPSC)-derived astrocytes, microglia, and oligodendrocytes.”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple studies on astrocytes, microglia, and oligodendrocytes derived from iPSCs demonstrate an important role for ApoE4 in cholesterol metabolism pathways.6”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Along the same lines, ApoE4 increased the number and size of early endosomes in AD patients (Cataldo et al., 2000) and in neurons derived from induced pluripotent stem cells (Lin et al., 2018).”
From Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer’s disease (2018) · cites this paper as Lin et al., 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this regard, transcriptomic studies of ApoE4 astrocytes deriving from human-induced pluripotent stem cells (hiPSCs) of AD patients demonstrated that lipid metabolism is one of main altered processes [15,16].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, it has been shown that cholesterol homeostasis is also impaired in ApoE4 astrocytes, although controversial data concerning intracellular and secreted cholesterol levels are present in literature depending on the different experimental model employed [15,16,24].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, although both groups could perform phagocytosis, both the percentage of phagocytic cells and the phagocytic index were lower in AD than in healthy control iMGs (Fig. 2H, Supplementary Fig. 2F), as has been previously reported in human iPSC-derived microglia with altered expression of AD risk genes [60–64].”
From microRNA-132 attenuates inflammation in induced pluripotent stem cell-derived microglia from Alzheimer’s disease patients (2026) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notable shared features include reduced phagocytosis, previously reported in human iPSC-derived microglia with altered expression of AD risk genes [60–64], and increased expression of inflammatory genes (such as complement C3), consistent with findings from human AD brain and APOE4/4 iPSC-derived microglia [52, 60, 61].”
From microRNA-132 attenuates inflammation in induced pluripotent stem cell-derived microglia from Alzheimer’s disease patients (2026) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, iPSC-derived microglia with altered expression of the sAD risk genes APOE4 and TREM2 display pronounced phenotypic differences from control microglia, such as impaired phagocytosis, whereas mutations involved in familial AD have a more limited impact on microglial function [51, 60–63, 119–122].”
From microRNA-132 attenuates inflammation in induced pluripotent stem cell-derived microglia from Alzheimer’s disease patients (2026) · cites this paper as [60]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The APOE genotype has a widespread impact on cell-autonomous and non-autonomous biological processes14.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“APOE ε4 is known to disrupt lipid homeostasis and immune response and to cause mitochondrial dysfunction [31–34]”
From Protective PLCG2 variants associate with a delayed onset of Alzheimer’s disease among heterozygous APOE ε4 carriers (2026) · cites this paper as [32]
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, astrocytes generated from hiPSC derived from fibroblasts obtained from patients with CNS diseases (usually with a genetic mutation causative of disease or a risk polymorphism) show pathological phenotypes, including dysregulation of lipid metabolism11, alteration in the contents of the extracellular vesicles released by astrocytes80, reduced autophagy81, or altered STAT3 signaling82”
From Reactive astrocyte nomenclature, definitions, and future directions (2021) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“are rapidly becoming commonplace in basic research11,82 and therapy development109”
From Reactive astrocyte nomenclature, definitions, and future directions (2021) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 microglia-like hiPSCs show decreased phagocytosis and increased inflammatory genes relative to APOE3 microglia143.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [143]
The cited source says what the claim attributes to it.
In the citing paper
“These results demonstrate an isoform-dependent regulation of APOE protein levels, as was previously shown for E3 and E4 in vitro, or in patient cerebrospinal fluid (CSF) (Lin et al., 2018; Mahley, 2016).”
From APOE2, E3, and E4 differentially modulate cellular homeostasis, cholesterol metabolism, and inflammatory response in isogenic iPSC-derived astrocytes (2022) · cites this paper as Lin et al., 2018
The cited source says what the claim attributes to it.
In the citing paper
“ApoE4 astrocytes displayed reduced levels of ApoE and impaired Aβ clearance compared with ApoE3 astrocytes”
From ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes (2023) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“ApoE4 astrocytes displayed reduced levels of ApoE and impaired Aβ clearance compared with ApoE3 astrocytes”
From ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes (2023) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“we found a significant accumulation of cholesterol in ApoE4 astrocytes compared with ApoE3 astrocytes”
From ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes (2023) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“because ApoE is also expressed in neurons under stress conditions (Xu et al., 2006), neurons cultured in vitro (Lin et al., 2018; Xu et al., 1999b), and neurons of selected brain regions in vivo (Han et al., 1994; Xu et al., 1999a)”
From ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism (2021) · cites this paper as Lin et al., 2018
The cited source says what the claim attributes to it.
In the citing paper
“In agreement with our data, significantly reduced ApoE levels were also observed in hiPSC-derived ApoE4 astrocytes [15,16,24], as well as in brain homogenates from mouse models expressing the human ApoE4 isoform [43,44].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“These results, together with those obtained by transcriptomic and proteomic analyses of hiPSC-derived astrocytes [15,16], further confirm that lipid metabolism is one of the main altered processes in ApoE4 astrocytes.”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [16]
In the citing paper
“and that the APOE ε4 variant associated with increased risk of Alzheimer’s Disease causes functional changes in neurons, astrocytes and microglia9.”
From CRISPR-based functional genomics for neurological disease (2020) · cites this paper as [9]
In the citing paper
“Furthermore, iPSC-derived cell types from different lineages can be combined into defined three-dimensional cultures, termed assembloids9,94–98.”
From CRISPR-based functional genomics for neurological disease (2020) · cites this paper as [9]
In the citing paper
“APOE ε4 also affects properties of iPSC-derived astrocytes and microglia, notably reducing their ability to clear Aβ9,102.”
From CRISPR-based functional genomics for neurological disease (2020) · cites this paper as [9]
In the citing paper
“Alterations of ApoE synthesis and release have been shown to characterize hiPSCs-derived ApoE4 astrocytes [15,16,24].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [16]
In the citing paper
“studies suggest that lower levels of ApoE receptors in the astrocytic membrane may lead to the reduced ability of ApoE4 astrocytes to clear Aβ [16,73].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [16]
In the citing paper
“ApoE4 has been shown to impact on many physiological functions played by astrocytes, affecting their ability to clear Aβ, to uptake glutamate, to promote neuronal synaptogenesis, and to maintain lipid homeostasis [15,16,42].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [16]
In the citing paper
“Our results further highlight the link between cholesterol metabolism, astrocyte dysfunction and neurodegeneration, emphasizing the role of cholesterol exposure in driving astrocyte-mediated neurotoxicity70–72.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,724
Flagged first, then by citations
1 of the 74 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 1,002
Towards Advanced iPSC-based Drug Development for Neurodegenerative Disease
Pasteuning-Vuhman, S., de Jongh, R., Timmers, A., & Pasterkamp, R. J. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.013 · Cited by 72
Low-Density Lipoprotein Cholesterol and Alzheimer's Disease: A Systematic Review and Meta-Analysis
Zhou, Z., Liang, Y., Zhang, X., Xu, J., Lin, J., Zhang, R., Kang, K., Liu, C., Zhao, C., & Zhao, M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00005 · Cited by 73
Kenkhuis, B., van Eekeren, M., Parfitt, D. A., Ariyürek, Y., Banerjee, P., Priller, J., van der Weerd, L., & van Roon‐Mom, W. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.04.006 · Cited by 71
BACE-1 inhibition facilitates the transition from homeostatic microglia to DAM-1
Singh, N., Benoit, M., Zhou, J., Das, B., Dávila-Velderrain, J., Kellis, M., Tsai, L., Hu, X., & Yan, R. (2022) · Science Advances · doi:10.1126/sciadv.abo1286 · Cited by 72
Self-citationRyan, S. K., Gonzalez, M. V., Garifallou, J. P., Bennett, F. C., Williams, K. S., Sotuyo, N. P., Mironets, E., Cook, K., Hakonarson, H. H., Anderson, S. A., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.02.010 · Cited by 65
Curcumin, inflammation, and neurological disorders: How are they linked?
Garodia, P., Hegde, M., Kunnumakkara, A. B., & Aggarwal, B. B. (2023) · Integrative Medicine Research · doi:10.1016/j.imr.2023.100968 · Cited by 77
Organoids to study immune functions, immunological diseases and immunotherapy
Ye, W., Luo, C., Li, C., Huang, J., & Liu, F. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.027 · Cited by 67
Genome Editing in iPSC-Based Neural Systems: From Disease Models to Future Therapeutic Strategies
McTague, A., Rossignoli, G., Ferrini, A., Barral, S., & Kurian, M. A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.630600 · Cited by 67
Dissecting the complexities of Alzheimer disease with in vitro models of the human brain
Blanchard, J., Victor, M. B., & Tsai, L. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00578-6 · Cited by 68
Self-citationAstrocytes and microglia in neurodegenerative diseases: Lessons from human in vitro models
Franklin, H., Clarke, B. E., & Patani, R. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101973 · Cited by 66
Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway
Narasimhan, S., Holtzman, D. M., Apostolova, L. G., Cruchaga, C., Masters, C. L., Hardy, J., Villemagne, V. L., Bell, J. S., Cho, M., & Hampel, H. J. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01669-5 · Cited by 70
Present Application and Perspectives of Organoid Imaging Technology
Fei, K., Zhang, J., Yuan, J., & Xiao, P. (2022) · Bioengineering · doi:10.3390/bioengineering9030121 · Cited by 65
Studying Human Neurodevelopment and Diseases Using 3D Brain Organoids
Tian, A., Muffat, J., & Li, Y. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.0519-19.2019 · Cited by 68
Intracellular Trafficking Mechanisms of Synaptic Dysfunction in Alzheimer’s Disease
Perdigão, C., Barata, M. A., Araújo, M. N. C. D. F., Mirfakhar, F. S., Castanheira, J., & Almeida, C. G. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00072 · Cited by 66
La Cunza, N., Tan, L. X., Thamban, T., Germer, C. J., Rathnasamy, G., Toops, K. A., & Lakkaraju, A. (2021) · JCI Insight · doi:10.1172/jci.insight.142254 · Cited by 65
Modulation of β-Amyloid Fibril Formation in Alzheimer’s Disease by Microglia and Infection
Brown, M. R., Radford, S. E., & Hewitt, E. W. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.609073 · Cited by 67
The Role of Astrocytes in Synapse Loss in Alzheimer's Disease: A Systematic Review
Hulshof, L. A., van Nuijs, D., Hol, E. M., & Middeldorp, J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.899251 · Cited by 66
Dias, D., Portugal, C. C., Relvas, J. B., & Socodato, R. (2025) · Cells · doi:10.3390/cells14040243 · Cited by 71
Ji, Y., Chen, X., Wang, Z., Meek, C. J., McLean, J. L., Yang, Y., Yuan, C., Rochet, J., Liu, F., & Xu, R. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03041-w · Cited by 74
Chernick, D., Ortiz‐Valle, S., Jeong, A., Qu, W., & Li, L. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134306 · Cited by 64
Glia in Neurodegeneration: The Housekeeper, the Defender and the Perpetrator
Sheeler, C. A., Rosa, J. S., Ferro, A., McAdams, B. D., Borgenheimer, E., & Cvetanović, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239188 · Cited by 61
Pushing the boundaries of brain organoids to study Alzheimer’s disease
Cerneckis, J., Bu, G., & Shi, Y. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.05.007 · Cited by 63
Cao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
Role of Neuron and Glia in Alzheimer’s Disease and Associated Vascular Dysfunction
Bandyopadhyay, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.653334 · Cited by 64
ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease
Li, Y., Macyczko, J. R., Liu, C.-C., & Bu, G. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.03.011 · Cited by 61
Patel, T., Carnwath, T., Wang, X., Allen, M., Lincoln, S., Lewis‐Tuffin, L. J., Quicksall, Z., Lin, S., Tutor‐New, F. Q., Ho, C. C. G., et al. (2022) · Aging Cell · doi:10.1111/acel.13606 · Cited by 61
Non-Coding RNAs as Novel Regulators of Neuroinflammation in Alzheimer’s Disease
Liu, Y., Cheng, X. M., Li, H., Hui, S., Zhang, Z., Yang, X. J., & Peng, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908076 · Cited by 63
Somogyi, A., Kirkham, E. D., Lloyd‐Evans, E., Winston, J., Allen, N. D., Mackrill, J. J., Anderson, K. E., Hawkins, P. T., Gardiner, S. E., Waller‐Evans, H., et al. (2023) · Journal of Cell Science · doi:10.1242/jcs.259875 · Cited by 65
Effects of APOE4 allelic dosage on lipidomic signatures in the entorhinal cortex of aged mice
Miranda, A. M., Ashok, A., Chan, R. B., Zhou, B., Xu, Y., McIntire, L. B., Area-Gomez, E., Di Paolo, G., Duff, K. E., Oliveira, T. G., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01881-6 · Cited by 60
Apolipoprotein E and viral infection: Risks and Mechanisms
Chen, F., Ke, Q., Wei, W., Cui, L., & Wang, Y. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.07.031 · Cited by 60
Sabogal-Guáqueta, A. M., Marmolejo-Garza, A., de Pádua, V. P., Eggen, B. J. L., Boddeke, E., & Dolga, A. M. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101805 · Cited by 65
Fernandez, H. R., Varma, A., Flowers, S. A., & Rebeck, G. W. (2020) · Cancers · doi:10.3390/cancers12123842 · Cited by 65
A role of low-density lipoprotein receptor-related protein 4 (LRP4) in astrocytic Aβ clearance
Zhang, H., Chen, W., Tan, Z., Zhang, L., Dong, Z., Cui, W., Zhao, K., Wang, H., Jing, H., Cao, R., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0250-20.2020 · Cited by 58
A New Hypothesis for Alzheimer’s Disease: The Lipid Invasion Model
Rudge, J. D. (2022) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210299 · Cited by 58
Modeling Traumatic Brain Injury in Human Cerebral Organoids
Ramírez, S., Mukherjee, A., Sepulveda, S. E., Becerra-Calixto, A., Bravo‐Vasquez, N., Gherardelli, C., Chavez, M., & Soto, C. A. (2021) · Cells · doi:10.3390/cells10102683 · Cited by 62
Park, Y., Chung, T. S., Lee, G., & Rogers, J. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00639 · Cited by 62
Söderberg, L., Johannesson, M., Gkanatsiou, E., Nygren, P., Fritz, N., Zachrisson, O., Rachalski, A., Svensson, A.-S., Button, E. B., Dentoni, G., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-61691-2 · Cited by 62
Larramona-Arcas, R., González-Arias, C., Perea, G., Gutiérrez, A., Vitorica, J., García-Barrera, T., Gómez-Ariza, J. L., Pascua-Maestro, R., Ganfornina, M. D., Kara, E., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00382-8 · Cited by 56
A review of protocols for brain organoids and applications for disease modeling
Mayhew, C. N., & Singhania, R. (2022) · STAR Protocols · doi:10.1016/j.xpro.2022.101860 · Cited by 58
Dissecting Alzheimer's disease pathogenesis in human 2D and 3D models
Cenini, G., Hebisch, M., Iefremova, V., Flitsch, L. J., Breitkreuz, Y., Tanzi, R. E., Kim, D. Y., Peitz, M., & Brüstle, O. (2020) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103568 · Cited by 60
Venkataraman, L., Fair, S. R., McElroy, C. A., Hester, M. E., & Fu, H. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10068-9 · Cited by 55
Metabolic perspective of astrocyte dysfunction in Alzheimer's disease and type 2 diabetes brains
Shen, Z., Li, Z., Yu, M., Tan, K.-L., & Chen, S. X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114206 · Cited by 53
Triglyceride metabolism controls inflammation and microglial phenotypes associated with APOE4
Stephenson, R. A., Sepulveda, J., Johnson, K. R., Lita, A., Gopalakrishnan, J., Acri, D. J., Beilina, A., Cheng, L., Yang, L. G., Root, J. T., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115961 · Cited by 55
Functional genomics and the future of iPSCs in disease modeling
Brooks, I. R., Garrone, C. M., Kerins, C., Kiar, C. S., Syntaka, S., Xu, J. Z., Spagnoli, F. M., & Watt, F. M. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.03.019 · Cited by 54
Degl’Innocenti, E., & Dell’Anno, M. T. (2023) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2023.1130729 · Cited by 55
Gao, C., Shi, Q., Pan, X., Chen, J., Zhang, Y., Lang, J., Wen, S., Liu, X., Cheng, T., & Lei, K. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113892 · Cited by 57
Promoting Alzheimer’s disease research and therapy with stem cell technology
Cao, Z., Kong, F., Ding, J., Chen, C., He, F., & Deng, W. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03737-w · Cited by 60
Haenseler, W., & Rajendran, L. (2019) · Stem Cells · doi:10.1002/stem.2995 · Cited by 58
Cellular complexity in brain organoids: Current progress and unsolved issues
Mansour, A. A., Schafer, S. T., & Gage, F. H. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.05.013 · Cited by 52
Cerebral organoids as tools to identify the developmental roots of autism
Chan, W. K., Griffiths, R., Price, D. J., & Mason, J. O. (2020) · Molecular Autism · doi:10.1186/s13229-020-00360-3 · Cited by 58
In Vivo Chimeric Alzheimer’s Disease Modeling of Apolipoprotein E4 Toxicity in Human Neurons
Najm, R., Zalocusky, K. A., Zilberter, M., Yoon, S. Y., Hao, Y., Koutsodendris, N., Nelson, M., Rao, A., Taubes, A., Jones, E. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107962 · Cited by 52
Sun, Y., Wei, K., Liao, X., Wang, J., Gao, L., & Pang, B. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5580 · Cited by 63
Kou, J., Wang, M., Shi, J., Zhang, H., Pu, X., Song, S., Yang, C., Yan, Y., Döring, Y., Xie, X., et al. (2021) · ACS Omega · doi:10.1021/acsomega.0c04810 · Cited by 52
Porciúncula, L. O., Goto‐Silva, L., Ledur, P. F., & Rehen, S. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.674563 · Cited by 54
Strong, C. E., Zhang, J., Carrasco, M., Kundu, S., Boutin, M. E., Vishwasrao, H. D., Liu, J., Medina, A., Chen, Y., Wilson, K. M., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05582-8 · Cited by 53
The role of glia in protein aggregation
Li, Q., & Haney, M. S. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105015 · Cited by 54
Lee, H., Aylward, A. J., Pearse, R. V., Lish, A. M., Hsieh, Y.-C., Augur, Z. M., Benoit, C. R., Chou, V., Knupp, A., Pan, C., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112994 · Cited by 58
All Together Now: Modeling the Interaction of Neural With Non-neural Systems Using Organoid Models
Chukwurah, E., Osmundsen, A. M., Davis, S. W., & Lizarraga, S. B. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00582 · Cited by 51
Ginseng gintonin, aging societies, and geriatric brain diseases
Choi, S.-H., Lee, R., Nam, S. M., Kim, D.-G., Cho, I., Kim, H., Cho, Y., Rhim, H., & Nah, S.-Y. (2020) · Integrative Medicine Research · doi:10.1016/j.imr.2020.100450 · Cited by 51
Gene Therapy Strategies Targeting Aging-Related Diseases
Yu, J., Li, T., & Zhu, J. (2022) · Aging and Disease · doi:10.14336/ad.2022.00725 · Cited by 52
Acharya, P., Choi, N. Y., Shrestha, S., Jeong, S., & Lee, M. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28606 · Cited by 50
Alzheimer’s disease pathogenesis: standing at the crossroad of lipid metabolism and immune response
Wang, Z., Zhang, L., & Qin, C. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00857-6 · Cited by 60
Modeling neurological disorders using brain organoids
Zhang, D. Y., Song, H., & Ming, G. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.05.026 · Cited by 53
Yang, A., Kantor, B., & Chiba‐Falek, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031244 · Cited by 51
Chatterjee, M., Özdemir, S., Kunadt, M., Koel‐Simmelink, M., Boiten, W., Piepkorn, L., Pham, T. V., Chiasserini, D., Piersma, S. R., Knol, J. C., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13066 · Cited by 47
Effect of APOE alleles on the glial transcriptome in normal aging and Alzheimer’s disease
Serrano-Pozo, A., Li, Z., Noori, A., Nguyen, H. N., Mezlini, A., Li, L., Hudry, E., Jackson, R. J., Hyman, B. T., & Das, S. (2021) · Nature Aging · doi:10.1038/s43587-021-00123-6 · Cited by 49
Wang, T., Huynh, K., Giles, C., Mellett, N. A., Duong, T., Nguyen, A., Lim, W. L. F., Smith, A., Olshansky, G., Cadby, G., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12538 · Cited by 43
Nutritional metabolism and cerebral bioenergetics in Alzheimer's disease and related dementias
Yassine, H. N., Self, W. K., Kerman, B. E., Santoni, G., Shanmugam, N. K. N., Abdullah, L. I., Golden, L. R., Fonteh, A. N., Harrington, M. G., Gräff, J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12845 · Cited by 52
Self-citationMalvaso, A., Gatti, A., Negro, G., Calatozzolo, C., Medici, V., & Poloni, T. E. (2023) · Cells · doi:10.3390/cells12242824 · Cited by 54
Quiroz‐Baez, R., Hernández‐Ortega, K., & Martínez‐Martínez, E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.580030 · Cited by 52
Physiological and Pathological Ageing of Astrocytes in the Human Brain
Verkerke, M., Hol, E. M., & Middeldorp, J. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03256-7 · Cited by 51
Phosphoproteomics identifies microglial Siglec‐F inflammatory response during neurodegeneration
Morshed, N., Ralvenius, W. T., Nott, A., Watson, L. A., Rodriguez, F. H., Akay, L. A., Joughin, B. A., Pao, P., Penney, J., LaRocque, L. M., et al. (2020) · Molecular Systems Biology · doi:10.15252/msb.20209819 · Cited by 48
Self-citationCRISPR/Cas9 genome editing for neurodegenerative diseases
Nojadeh, J. N., Eryilmaz, N. S. B., & Ergüder, B. İ. (2023) · EXCLI journal · doi:10.17179/excli2023-6155 · Cited by 53
Penney, J., Ralvenius, W. T., Loon, A., Cerit, O., Dileep, V., Milo, B., Pao, P., Woolf, H., & Tsai, L. (2024) · Glia · doi:10.1002/glia.24485 · Cited by 52
Self-citationBerry, B. J., Smith, A. S. T., Young, J. E., & Mack, D. L. (2018) · Cells Tissues Organs · doi:10.1159/000493018 · Cited by 47
Phagocytosis of Apoptotic Cells Is Specifically Upregulated in ApoE4 Expressing Microglia in vitro
Muth, C., Hartmann, A., Falla, D. S., Glatzel, M., & Krasemann, S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00181 · Cited by 47
iPSC for modeling neurodegenerative disorders
Valadez-Barba, V., Cota-Coronado, A., Hernandez-Perez, O. R., Lugo-Fabres, P. H., Padilla‐Camberos, E., Díaz, N. F., & Diaz-Martinez, N. E. (2020) · Regenerative Therapy · doi:10.1016/j.reth.2020.11.006 · Cited by 49
The role of genetic risk factors of Alzheimer’s disease in synaptic dysfunction
Fu, W.-Y., & Ip, N. Y. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.07.011 · Cited by 48
Zhang, Z., Wang, X., Park, S. S., Song, H., & Ming, G. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.12.015 · Cited by 49
Engineered 3D immuno-glial-neurovascular human miBrain model
Stanton, A. E., Bubnys, A., Agbas, E., James, B. T., Park, D. S., Jiang, A. Y. L., Pinals, R. L., Liu, L., Truong, N., Loon, A. R., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2511596122 · Cited by 51
Self-citationContribution of astrocytes to metabolic dysfunction in the Alzheimer’s disease brain
Zulfiqar, S., Garg, P., & Nieweg, K. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0140 · Cited by 46
Revealing cell vulnerability in Alzheimer’s disease by single-cell transcriptomics
Saura, C. A., Deprada-Fernandez, Á., Capilla-López, M. D., & Parra‐Damas, A. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.05.007 · Cited by 48
Makrygianni, E. A., & Chrousos, G. P. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.621970 · Cited by 49
Optimization of cerebral organoids: a more qualified model for Alzheimer’s disease research
Bi, F.-C., Yang, X.-H., Cheng, X.-Y., Deng, W.-B., Guo, X.-L., Yang, H., Wang, Y., Li, J., & Yao, Y. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00252-3 · Cited by 49
Renner, H., Schöler, H. R., & Bruder, J. M. (2021) · Movement Disorders · doi:10.1002/mds.28775 · Cited by 47
Stem cell therapy for Alzheimer’s disease: An overview of experimental models and reality
Qin, C., Wang, K., Zhang, L., & Bai, L. (2022) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12207 · Cited by 49
Sen, T., & Thummer, R. P. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00564-w · Cited by 52
Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease
Campos‐Peña, V., Pichardo-Rojas, P. S., Sánchez-Barbosa, T., Ortíz-Islas, E., Rodríguez-Pérez, C. E., Montes, P., Ramos-Palacios, G., Silva‐Adaya, D., Quintana, R. V., Cerna-Cortés, J. F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012092 · Cited by 47
Ferro, A., Sheeler, C. A., Rosa, J. S., & Cvetanović, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.01.016 · Cited by 49
Modelling neurodegenerative disease using brain organoids
Wray, S. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.05.012 · Cited by 45
Ortiz‐Guerrero, G., González-Reyes, R. E., de‐la‐Torre, A., Medina-Rincón, G. J., & Nava-Mesa, M. O. (2020) · Brain Sciences · doi:10.3390/brainsci10060369 · Cited by 48
Generation of pure monocultures of human microglia-like cells from induced pluripotent stem cells
Banerjee, P., Paza, E., Perkins, E., James, O. G., Kenkhuis, B., Lloyd, A. F., Burr, K., Story, D., Yusuf, D., He, X., et al. (2020) · Stem Cell Research · doi:10.1016/j.scr.2020.102046 · Cited by 48
Roles of physical exercise in neurodegeneration: reversal of epigenetic clock
Xu, M., Zhu, J., Liu, X.-D., Luo, M.-Y., & Xu, N.-J. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00254-1 · Cited by 46
Ren, X., Yao, L., Wang, Y., Mei, L., & Xiong, W.-C. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02422-0 · Cited by 42
A multi‐hit hypothesis for an APOE4 ‐dependent pathophysiological state
Steele, O. G., Stuart, A. C., Minkley, L., Shaw, K., Bonnar, O., Anderle, S., Penn, A. C., Rusted, J., Serpell, L., Hall, C., et al. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15685 · Cited by 44
Novelli, G., Spitalieri, P., Murdocca, M., Centanini, E., & Sangiuolo, F. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1059579 · Cited by 43
Recent Trends and Perspectives in Cerebral Organoids Imaging and Analysis
Martin, C. B., Simon-Chane, C., Clouchoux, C., & Histace, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.629067 · Cited by 41
Current progress of cerebral organoids for modeling Alzheimer's disease origins and mechanisms
Sreenivasamurthy, S., Laul, M., Zhao, N., Kim, T., & Zhu, D. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10378 · Cited by 49
Human tau mutations in cerebral organoids induce a progressive dyshomeostasis of cholesterol
Glasauer, S. M. K., Goderie, S. K., Rauch, J. N., Guzman, E., Audouard, M., Bertucci, T., Joy, S., Rommelfanger, E., Luna, G., Keane-Rivera, E., et al. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.07.011 · Cited by 46
Rudajev, V., & Novotný, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01127-y · Cited by 52
Metadata
- Authors
- Lin, Y.-T., Seo, J., Gao, F., Feldman, H. M., Wen, H.-L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., Rueda, R., Kritskiy, O., Abdurrob, F., Peng, Z., Milo, B., Yu, C. J., Elmsaouri, S., Dey, D., Ko, T., Yankner, B. A., & Tsai, L.-H.
- Affiliations
- Massachusetts Institute of Technology (US)
- Harvard University (US)
- Corresponding author
- Tsai, Li-Huei
- ORCID
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 98
- Issue
- 6
- Pages
- 1141-1154.e7
- ISSN
- 0896-6273 (ISSN-L)
- PMC
- PMC6023751
- OpenAlex
- W2805798400
- Cited by
- 1,125
- References
- 74
- Citations by year
- 2026: 94 · 2025: 152 · 2024: 175 · 2023: 167 · 2022: 159 · 2021: 151 · 2020: 142 · 2019: 66 · 2018: 18
- FWCI
- 64.81
- Type
- journal article
- Language
- en
- Update notices
- erratum (2018-06-27)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neuron (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- IslandScholar (University of Prince Edward Island) (submittedVersion)
- Funders
- Basic Science Research Program (2014R1A6A3A03055359)
- NIH (RF1 AG048056, RC1 AG036106, RF1 AG048029)
- Glenn Foundation for Medical Research
- Robert A. and Renee E. Belfer Family Foundation
- Cure Alzheimer's Fund
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- APOE ε4, sporadic Alzheimer's disease, induced pluripotent stem cells, APOE3, neurons, astrocytes, microglia-like cells, amyloid-beta, synaptic function, lipid metabolism, cholesterol accumulation, cell type-specific gene expression, CRISPR/Cas9 genome editing
- MeSH terms
- Alzheimer Disease, Astrocytes, Brain, Cell Differentiation, Humans, Synaptic Transmission, Neuroglia, Neurons, Organoids, Peptide Fragments, Phosphoproteins, Amyloid beta-Peptides, tau Proteins, Microglia, Lipid Metabolism, Apolipoprotein E3, Apolipoprotein E4, Induced Pluripotent Stem Cells, Transcriptome, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
